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Abstract
Phyllanthus amarus Schum. & Thonn. has been used for the treatment of various diseases. Previous in vitro study
in human liver microsome demonstrated the inhibitory activity of P. amarus extract on CYP3A4, an enzyme responsible for
various drug metabolism. The objective of this study was to evaluate the effect of P. amarus ethanolic extract on the pharma-
cokinetics of midazolam, a CYP3A4 probe drug, in rabbits. Midazolam plasma concentration time-profiles (0-8 h) after a single
oral dose of 10 mg/kg midazolam were examined in rabbits receiving P. amarus extract compared to control. In treatment
group, P. amarus extract (500 mg/kg) was orally administered for 7 days and on the experiment day prior to midazolam
administration. The results showed that pretreatment with P. amarus significantly increased the mean maximum concentra-
tion (Cmax), time to reach maximum concentration (Tmax), area under curve (AUC0-8), and elimination half-life (T1/2) (2.9-,
1.6-, 2.8-, and 1.4-fold, respectively) compared with control group receiving a single oral dose of midazolam. The results
suggest that P. amarus extract inhibits midazolam metabolism in rabbits probably by inhibition of CYP3A which is the enzyme
responsible for midazolam metabolism. Therefore, coadministration of P. amarus and drugs which are CYP3A substrates may
increase plasma drug concentration leading to serious side effects. Thus, concern over the clinical relevance of herb-drug
interaction between P. amarus and CYP3A substrates should be warranted. However, further investigation is needed to be
performed in human to reveal the clinically significant potential of these herb-drug interactions.
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1. Introduction
Phyllanthus amarus Schum.&Thonn., belonging to
the family Euphorbiaceae, is a medicinal plant that has been
used  in  traditional  Thai  medicine  for  treatment  of  fever,
jaundice, ascites, hemorrhoid, and diabetes (Pongboonrod,
1976). Several pharmacological activities of P. amarus have
been  reported  including  antiamnesic,  antibacterial,  anti-
fungal, antiviral, anticancer, anti-diarrheal, gastroprotective,
antiulcer, analgesic, anti-inflammatory, antioxidant, diuretic,
antiplasmodial, aphrodisiac, contraceptive, antihypertensive,
hepatoprotective against ethanol-, paracetamol-, and carbon
tetrachloride-toxicity, hypoglycemic, hypocholesterolemic,
immunomodulatory, nephroprotective, radioprotective, and
spasmolytic activities (Patel et al., 2011, Pramyothin et al.,
2007, Wongnawa et al., 2006). The secondary metabolites
present in P. amarus are alkaloids (securinine, dihydro-
securinine,  etc.),  flavonoids  (quercetin,  astragalin,  rutin,
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kaempferol, etc.), ellagitannins (gallic acid, ellagic acid, etc.),
lignans  (phyllanthin,  hypophyllanthin,  niranthin,  etc.),
triterpines  (lupeol),  sterols,  and  volatile  oil  (Patel  et  al.,
2011). An alcoholic extract of P. amarus was found, in vivo
as well as in vitro, to inhibit some cytochrome P450 isozymes
(CYP 1A1, 1A2, 2B1/2, 2E1) which are responsible for
activation of various procarcinogens, suggesting its inhibi-
tory mechanism of action on carcinogenesis (Kumar and
Kuttan,  2006).  Moreover,  Taesotikul  et  al.  (2011)  have
reported the inhibitory potency of the ethanolic and aqueous
extract of P. amarus on CYP3A4 activity in vitro in human
liver microsome that was about 2-3 orders of magnitude
stronger than the known CYP3A4 inhibitors such as erythro-
mycin and clarithromycin suggesting its potential to cause
herb-drug interaction, since CYP 3A4 is an enzyme respon-
sible for metabolism of more than 50% of all drugs. Various
studies  have  demonstrated  that  inhibition  of  CYP3A4
increased plasma concentration of drugs which are CYP 3A4
substrate leading to serious side effects or toxicity (Norwack,
2008, Lilja et al., 2000, Westphal, 2000). Midazolam is a
sedative drug with a rapid onset and short duration of action.
After oral administration, maximum plasma levels are reached
within 30 min and the drug is rapidly eliminated from plasma
with the half-life of about 2 h. The oral bioavailability ranges
from 31-72%. It is rapidly and extensively metabolized by
CYP3A to 1-hydroxy and 4-hydroxy midazolam (Heizmann
et al., 1983, Patki et al., 2003, Reves et al., 1985). Therefore,
this study was aimed to investigate the effect of P. amarus
on the pharmacokinetics of midazolam, a CYP3A substrate,
in  rabbits  in  order  to  reveal  the  possibility  of  herb-drug
interaction between P. amarus and midazolam in vivo.
2. Materials and Methods
2.1 Chemicals and reagents
Midazolam tablets (Dormicum
®, Hoffmann-La Roche
Ltd., Basel, Switzerland) were purchased from the Food and
Drug Administration, Ministry of Public Health, Bangkok,
Thailand.  Standard  midazolam  and  diazepam  were  kindly
provided by Dr Wirachai Samai, The Forensic Medicine and
Toxicology Unit, Department of Pathology, Faculty of Medi-
cine, Prince of Songkla University. Standard phyllanthin and
hypophyllanthin  were  kindly  provided  by  Dr  Wanida
Sukketsiri, Department of Pharmacology, Faculty of Science,
PSU. Methanol and acetonitrile (HPLC grade) were purchased
from J.T. Baker. USA. All other chemicals and solvents were
of analytical reagent grade. Water was purified by Milli Q
Water Purification System, Millipore, USA.
2.2 Preparation of P. amarus extract
P. amarus powder was purchased from Lampang Herb
Conservation, Lampang province, Thailand, and was identi-
fied by Assoc. Prof. Tanomjit Supavita, School of Pharmacy,
Walailak University, Nakhon Si Thammarat. The powder was
extracted twice in 70% ethanol (1:5) at room temperature
for  7  days.  The  filtrate  was  evaporated  at  60°C  and  then
lyophillized. The yield of the extract was about 13% w/w. The
extract was stored in a well-closed, light protected container
at  -20°C  until  used.  A  portion  of  the  extract  was  freshly
reconstituted in 10% of gum acacia at desired concentrations
prior to the experiment.
2.3 Animals
Nine male New Zealand White rabbits, obtained from
The National Laboratory Animal Center, Mahidol University,
Salaya, Nakornpathom, Thailand, weighing between 3.0 - 3.5
kg, were housed at The Southern Laboratory Animal Facility,
Prince  of  Songkla  University,  Thailand,  under  controlled
environment (temperature 25±2°C and relative humidity of
approximately 60% with 12 h light/dark cycle). They received
standard pellet diet and water ad libitum and were acclima-
tized for 7 days, then fasted for 12 h before the experiment.
The  experimental  procedures  were  approved  by  the
Committee on Animal Care (Ref. 03/54) and were in accord-
ance  with  the  Guiding  Principles  for  the  Care  and  Use  of
Research Animals promulgated by Prince of Songkla Univer-
sity.
2.4 Study design
In phase 1, the baseline pharmacokinetics of mida-
zolam were evaluated in the animals receiving a single oral
dose of 10 mg/kg midazolam with 10 mL of water. In phase 2,
after a 1-week washout period, the animals were orally admin-
istered with 500 mg/kg P. amarus extract once a day (o.d.) for
7 days and the last dose in the morning on day 8, one hour
before midazolam administration. Blood samples (2 mL) were
taken  from  marginal  ear  vein  through  a  venous  catheter
before administration of midazolam (T0) and at 0.25, 0.5, 0.75,
1, 2, 3, 4, 6 and 8 h post dose. The heparinized plasma was
collected and stored at -20°C until analysed within 1 month.
2.5 Midazolam analysis
Midazolam concentration in plasma was determined
by HPLC method modified from Lehmann and Boulieu (1995).
To the 250 L of plasma sample, 100 L of 0.1 N NaOH, 50 L
internal standard (diazepam in methanol, 3 g/mL) and 1 mL
of diethyl ether were added. The mixture was vortex-mixed
for 5 minutes and centrifuged at 1,000 g for 10 minutes. The
800 L of upper organic phase was separated and evaporated
at 35°C under air flow. The residue was reconstituted in 100
L of the mobile phase and 50 L was injected into the HPLC
system  (Agilent  Technologies)  using  C8  reversed-phase
column (Phenomenex Inc, USA). The mobile phase consisted
of 0.025 M KH2PO4 (pH 4.6):acetonitrile:methanol (35:30:35
v/v/v), at a flow rate of 1.2 mL/min. The peak was detected
using a UV detector set at 210 nm. The standard midazolam
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respectively.  The  assay  was  validated  according  to  the
guideline (US. FDA, 2001) with the lower limit of quantifica-
tion (LLOQ) of 50 ng/mL. The interday and intraday accura-
cies(104-110% and 95-100%, respectively), precision (% CV
less than 10) and mean recovery (86-99%) were within the
accepted ranges.
2.6 Phyllanthin and hypophyllanthin analysis
2.6.1  In P. amarus extract
The sample solution of P. amarus extract was prepared
by  accurately  weighing  1  g  dry  powder  extract  and  dis-
solving in 10 mL of methanol, then centrifuging at 1,300 g for
10 min. The supernatant was transferred into a microcentri-
fuge tube and diluted to 10 g/mL and 20 L was injected
into the HPLC system (Agilent Technologies) using C18
reversed-phase column (Symmetry
®, Waters, USA). The
mobile phase consisted of acetonitrile:water (52:48 v/v), at
a flow rate of 1.0 mL/min. The peak was detected using a UV
detector set at 220 nm. The experiment was run in triplicate.
Standard calibration curves were constructed by the least-
square linear regression of phyllanthin and hypophyllanthin
concentration and their peak areas. The concentrations of
phyllanthin and hypophyllanthin in P. amarus extract were
calculated from the standard curve by reverse prediction.
2.6.2  In plasma
Phyllanthin  and  hypophyllanthin  concentration  in
plasma were determined by HPLC method modified from
Murugaiyah  and  Chan  (2007).  To  the  250 L  of  plasma
sample, 50 L of internal standard (diazepam in methanol,
3 g/mL) and 250 L of acetonitride were added then vortex-
mixed for 1 minute and centrifuged at 1,000 g for 10 minutes.
The supernatant (50 L) was injected into HPLC system
(Agilent Technologies) using C18 reversed-phase column
(Symmetry
®, Waters, USA). The mobile phase consisted of
acetonitrile:water (52:48 v/v), at a flow rate of 1.0 mL/min. The
peak was detected using a UV detector set at 220 nm. The
internal standard (diazepam), standard phyllanthin and
hypophyllanthin were eluted at 5, 10.2 and 10.8 min, respec-
tively. The assay was validated according to the guideline
(US. FDA, 2001). The LLOQ were 211.18 ng/mL and 226.62
ng/mL for phyllanthin and hypophyllanthin, respectively.
The intraday accuracy (85-106%), interday accuracy (91-
108%), precision (% CV less than 10) and mean recovery (84 -
102%) were within the accepted ranges.
2.7 Pharmacokinetics and statistical analysis
Plasma concentrations of midazolam were plotted
against time after the drug administration. Pharmacokinetic
parameters of midazolam were determined by a noncompart-
ment  method  with  the  use  of  WinNonlin  Professional
Software Version 1.1 (Pharsight, Mountain View, CA). The
areas under the drug concentration-time (AUC) curves from
0 to 8 h (AUC0-8) were calculated using the linear trapezoidal
method from time 0 to 8 h after midazolam administration.
The areas under the drug concentration time curves from zero
to infinity  0 (AUC )   were calculated by the sum of AUC0-8
and ratio of the concentration at 8 h to the elimination rate
constant (Ke). The maximum plasma concentrations (Cmax) and
the time to reach Cmax (Tmax) were obtained from the actual
data. Clearance (CL/F) was calculated as dose/ 0 AUC . The
elimination rate constant was obtained from the slope of the
terminal log linear concentration-time value. Half life (T1/2),
the time for concentration to decrease by half, was calculated
by ratio of 0.693/Ke. All pharmacokinetic parameters were
expressed as the mean ± standard deviation (X±SD). Statisti-
cal  analysis  was  performed  using  Student’s  paired  t-test.
Differences were considered as statistically significant when
the p-value was less than 0.05. The software used was the
SPSS (Version 11.5, SPSS Inc, Chicago, IL, USA).
3. Results
The contents of phyllanthin and hypophyllanthin in
P. amarus extract were 296.69±8.04 mg/g and 96.56±4.36
mg/g, respectively. Mean plasma concentration time-profiles
of midazolam after a single oral dose of 10 mg/kg midazolam
(Phase 1) and after pretreatment with 500 mg/kg P. amarus
o.d. orally for 7 days and once before midazolam administra-
tion (Phase 2) are shown in Figure 1. The mean Cmax(164.87±
140.15 VS 474.15±322.46 ng.mL), Tmax(0.44±0.27 VS 0.72±0.29
h), AUC0-8(362.39±281.88 VS 1024.78±1094.74 ng.h/mL) and
T1/2(2.19±1.12 VS 3.18±1.49 h) of midazolam were significantly
increased after pretreatment with P. amarus, whereas the
0 AUC (439.76±360.02 VS 1424.27±1749.62 ng.h/mL) was
non-significantly increased, Ke(0.39±0.19 VS 0.26±0.18 h
-1)
and CL/F(0.08±0.10 VS 0.02±0.02 L/h/kg) were non-signifi-
cantly decreased (Table 1). Phyllanthin and hypophyllanthin
Figure 1. Mean plasma concentration-time profiles of midazolam
in  rabbit  (N=9)  after  a  single  oral  dose  of  10  mg/kg
midazolam (Phase 1) and after pretreatment with 500 mg/
kg  P. amarus  o.d.  orally  for  7  days  and  once  before
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were undetectable in all plasma samples at one hour after
oral administration of the last dose of P. amarus.
4. Discussion and Conclusions
Some phytochemicals contained in medicinal plants
are  biologically  active  and  capable  of  interacting  with
therapeutic drugs. Inhibition or induction of drug metaboliz-
ing enzymes, particularly CYPs that are the major enzymes
responsible for the metabolism of most therapeutic drugs, is
of major concern. The induction of CYP may decrease plasma
concentration of certain drugs, leading to reduced efficacy
of the drug or treatment failure. On the other hand, an inhibi-
tory effect of medicinal plants on CYP may cause increased
plasma concentrations of several drugs leading to increased
efficacy, side effect or toxicity of the drug (Elvin-Lewis, 2001).
Among these CYP enzymes, CYP3A4 is the most abundant in
human liver, as well as in intestine, and is involved in the
metabolism of more than 50% of all prescribed drugs (Zhou
et al., 2008). Induction or inhibition of CYP3A4 by various
herbs  has  been  reported  to  be  clinically  important.  For
example,  administration  of  St. John’s  Wort  (Hypericum
perforatum, a CYP 3A4 inducer) extract to patients receiving
tacrolimus, an immunosuppressive drug, markedly reduced
tacrolimus blood concentration with the risk of organ rejec-
tion (Mai et al., 2003) and coadministration of simvastatin
(a  lipid  lowering  drug)  with  grapefruit  juice  (a  CYP  3A4
inhibitor) increased the mean peak serum concentration of
simvastatin 12.0-fold with increase risk for myopathy (Lilja
et al., 2000). In the present study, the effect of P. amarus
ethanolic  extract  on  midazolam  pharmacokinetics  was
examined in rabbits in order to determine the inhibitory effect
of  P. amarus  on  CYP3A  in vivo  using  midazolam  as  a
substrate probe. Midazolam is a sedative drug with a rapid
onset and short duration of action (Reves et al.,1985). It is
rapidly and extensively metabolized by CYP3A to 1-hydroxy
and 4-hydroxy midazolam (Patki et al., 2003). Midazolam is
one of the best in vivo probe drugs for the study of CYP3A4
activity not only because it is a substrate of CYP 3A, but it is
unaffected by P-glycoprotein or other known transporters
and presents negligible adverse effects at the dose used for
probe studies (Bjornsson et al., 2003; Galetin et al., 2005;
Zhou  et  al.,  2008).  It  can  provide  a  measure  of  human
CYP3A4 and 3A5 activity related to both intestinal and
hepatic metabolism, respectively (Lin et al., 2002). Moreover,
midazolam hydroxylase activity could be determined in rabbit
as well as in human hepatic microsomes (Elbarbry et al.,
2009) suggesting that the data obtained by using rabbit as an
animal model can be applied to determine CYP3A activity in
human. Although the isoform found in rabbit is CYP3A6 while
those found in human are CYP3A4/3A5 (Daujat et al., 1991;
Patki et al., 2003), it has been demonstrated that CYP 3A6
is strongly similar to CYP3A4 both in intestine and liver
(McKinnon et al., 1993, Franklin, 1995).
It was found from this study that oral pretreatment of
P. amarus ethanolic extract (500 mg/kg, daily for 7 days and
once 1 h before midazolam) increased Cmax, AUC0-8 and T1/2
(2.9, 2.8 and 1.4-fold, respectively) of midazolam indicating
the inhibitory activity of P. amarus on CYP3A, the enzyme
responsible  for  midazolam  metabolism.  Although  a  large
variation was noticed, it is consistent with previous in vitro
and in vivo reports showing large interindividual variability
in genetic expression for CYP3A leading to variability (20-
60 fold) of oral bioavailability and metabolism of CYP3A
substrates  (Thummel  et  al.,  1994;  Thummel  et  al., 1996;
Wilkinson, 1996). According to the drug interaction guideline
(US FDA, 2006), P. amarus in this study was classified as a
moderate CYP 3A inhibitor because the increase in the area
under curve of oral midazolam was in the range of 2-5 fold.
This  inhibitory  effect  on  CYP3A  was  consistent  with
previous in vitro data showing that ethanolic extract of P.
amarus  and  its  major  lignans,  phyllanthin  and  hypo-
Table 1. Pharmacokinetic parameters (X ± SD) of midazolam in 9 rabbits
receiving a single oral dose of 10 mg/kg midazolam (Phase 1)
compared with after pretreatment with 500 mg/kg P. amarus o.d.
orally for 7 days and once before midazolam administration
(Phase 2).
Midazolam
  Parameters p-value
Phase 1 Phase 2
Tmax (h) 0.44±0.27 0.72±0.29* 0.030
Cmax (ng/L) 164.87±140.15 474.15±322.46* 0.004
AUC0-8 ( ng.h/L) 362.92±281.88 1024.78±1094.74* 0.048
0 AUC  ( ng.h/L) 439.76±360.02 1424.27±1749.62 0.050
T1/2 (h) 2.19±1.12 3.18±1.49* 0.038
Ke (h
-1) 0.39±0.19 0.26±0.18 0.141
CL/F (L/h/kg) 0.08±0.10 0.02±0.02 0.085
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phyllanthin, were potent mechanism-based inhibitors of CYP
3A4 activity in human liver microsome (Taesotikul et al.,
2011).  In  the  present  study,  P. amarus  ethanolic  extract
containing phyllanthin and hypophyllanthin 297 mg/g and
96  mg/g,  respectively,  showed  the  inhibitory  activity  on
CYP3A although the plasma concentration of phyllanthin
and hypophyllanthin could not be detected at the LLOQ of
211.18 and 226.62 ng/mL, respectively, whereas the IC50 in
in vitro study was 800 ng/mL (Taesotikul et al., 2011), and
the clearance of midazolam was not significantly decreased
which suggested that the inhibitory effect might take place
mainly in the intestine rather than in the liver. Moreover,
in vivo study in rats also showed that single dose administra-
tion of P. amarus ethanolic extract (800 mg/kg/day) increased
oral bioavailability of midazolam through inhibition of intes-
tinal CYP 3A since it was affected by oral but not intravenous
administration  (Taesotikul  et  al.,  2012).  Concerning  the
mechanism  of  inhibition,  CYP  inhibitors  that  have  been
shown to be mechanism-based inactivators require catalytic
activation by the enzyme to transient intermediates that then
form quasi-irreversible complexes with the heme iron atom of
the enzyme leading to inhibition (Hollenberg, 2002). This
might be one of the possible mechanisms of P. amarus to
inhibit  CYP  activity  since  P. amarus  has  been  shown  to
possess  iron  chelating  activity  (Wongnawa  et  al.,  2006;
Kumaran and Karunakaran, 2007). Moreover, deferasirox, a
well known iron chelator, as well as some phytochemicals
with iron chelating activity such as curcumin, quercetin and
catechin, also inhibit CYP activity (Morel et al., 1993; Chow
et al., 2006; Jiao et al., 2006; Leopoldini et al., 2006; Hatcher
et al., 2008; Skerjanec et al., 2010; Choi et al., 2011; Cho
et al., 2012; Galanello et al., 2012). It is noted that Tmax was
increased  after  pretreatment  with  P. amarus,  which  is
inconsistant with the inhibitory effect on intestinal CYP3A.
This effect might result from the delayed gastric emptying
effect which is attributed by the stringent effect of tannin,
a major component in P. amarus (Chaudhari and Mengi,
2006; Umoh et al., 2013).
In conclusion, the present study has demonstrated
that pretreatment with P. amarus ethanolic extract (500 mg/
kg) for a short period (7 days) increased the plasma level of
midazolam probably by inhibition of CYP3A. Since CYP 3A
is an enzyme responsible for the metabolism of various drugs,
co-administration of P. amarus may increase plasma level of
these  drugs  leading  to  increased  efficacy  or  serious  side
effects. Thus, clinical investigation needs to be performed
to reveal the significant potential of these herb-drug inter-
actions in human.
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